低风险MDS患者接受螯合治疗及不接受螯合治疗的24个月结局对比:一项前瞻性注册研究结果
This 5-year, prospective registry enrolled 600 lower-risk MDS patients (pts) with transfusional iron overload. Clinical outcomes were compared between chelated and nonchelated pts. At baseline, cardiovascular comorbidities were more common in non-chelated pts, and MDS therapy was more common in chelated pts. At 24 months, chelation was associated with longer median overall survival (52.2 months vs. 104.4 months; p < .0001) and a trend toward longer leukemia-free survival and fewer cardiac events. No differences in safety were apparent between groups. Limitations of this analysis included, varying time from diagnosis and duration of chelation, and the fact that the decision to chelate may have been influenced by pt clinical status.
主要结论:在24个月时,与不接受螯合治疗者相比,接受螯合治疗者的中位整体生存期更长,并具有无白血病生存期更长、心脏不良事件更少的趋势。
- 您可能感兴趣的文章
-